Investing in Psychedelic Biotech

​2025 has been the start of a bull period for psychedelic medicine.

• ​Psychedelic Biotechs like GH Research, Compass Pathways and Lykos Therapeutics are releasing impressive, late stage clinical trial data
  
  

• ​Capital is following the data: Cybin just raised $500M and Johnson and Johnson's Ketamine-inspired antidepressant Spravato broke $1B+ / year of topline.
  
  

• ​A new administration seems surprisingly interested in accelerating the FDA approval of psychedelics as treatments for mental health disorders
  

​Learn how top VCs and LPs are mapping and allocating to this exciting space in this special event designed for family offices and HNWIs.

​You will learn:

• ​The contrasting approaches that biotech and pharma are taking to commercialize psychedelic medicine
  
  

• ​Where we see the highest-leverage points for investing
  
  

• ​Lessons from past failures
  
  

• ​And of course there will be plenty of time for interaction and Q&A
  

​This event is run by Brom Rector and Sam Tabone of XEIA, a venture capital fund that invests in "Human 3 - the next epoch of human health, wellbeing and performance". As part of their Human 3 thesis, they have invested in 8 psychedelic medicine companies from pre-seed to pre-IPO.